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Abstract
In this study, we developed QSAR models for the anti-proliferative activity of pyrazolo-triazole hybrids [(1-benzyl-1H-1,2,3-
triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-yl) methanone] on human brain cancer (U87MG), lung cancer (A549), prostate cancer
(PC-3), and colon cancer (HT-29) cell lines. We employed K-means cluster analysis to split the data sets. Statistically robust models
were generated [pIC50 (U87MG): R  = 0.873, Q2 = 0.554, R2pred =  0.866; pIC50 (A549):  R  = 0.879, Q2 = 0.637, R2pred =  0.858; pIC50
(PC3):  R  = 0.953; Q2 = 0.850; R2pred =  0.796; pIC50 (HT-29):  R  = 0.962, Q2 = 0.891; R2pred =  0.707]. The reliability of these models
was confirmed by acceptable validation parameters, and these models also satisfied the Golbraikh and Tropsha acceptable model
criteria. The QSAR study highlighted the atomic feature and molecular descriptors, information content descriptors, and topological
and constitutional descriptors that affect anti-cancer activity.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The conventional drug discovery and development
cascade, from a theoretical concept to the market, con-
sumes almost 15 years with large monetary expenses
[1,2]. Computational methodologies have emerged as∗ Corresponding author. Tel.: +91 8827680414.
E-mail address: shovanlal.gayen@gmail.com (S. Gayen).
Peer review under responsibility of Taibah University.
http://dx.doi.org/10.1016/j.jtusci.2016.04.009
1658-3655 © 2016 The Authors. Production and hosting by Elsevier B.V. on 
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).a crucial component of the drug discovery process.
Many in silico tools have been developed to shorten
the drug discovery cycle to minimize the expense
and risk of failure [3,4]. Computer-aided drug design
(CADD) is an important method that can help from
hit identification to lead optimization and beyond
[5,6]. Computer-aided drug design (CADD) includ-
ing quantitative structure-activity relationships (QSAR),
pharmacophore modelling, molecular field analysis,
molecular docking and de novo drug design, which allowbehalf of Taibah University. This is an open access article under the
the development of predictive models for potential lead
candidate discovery and optimization [7,8].
Quantitative structure-activity relationship (QSAR)
modelling is used to find the relationship between an
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bserved activity and the corresponding structural fea-
ures of chemo types [9–15]. By predicting the biological
ctivity of a novel chemical entity from the QSAR mod-
ls, various molecular descriptors are calculated [16–21].
 large number of software programmes that are able
o calculate such molecular descriptors are available
ommercially as well as freely [9]. “PaDEL-Descriptor”
http://www.yapcwsoft.com/dd/padeldescriptor/) is a
remium QSAR modelling software that calculates 797
escriptors (663 1D, 2D descriptors, and 134 3D descrip-
ors) and 10 types of fingerprints [9,10].
Previously, we developed many QSAR models
or varieties of diseases, such as cancer and AIDS
12–17,19,21]. Now, our attention is focussed on a
eries of pyrazolo-triazole hybrids that exhibit promising
nti-proliferative properties, as reported by Reddy and
o-workers [22]. Thus far, no QSAR study on pyrazolo-
riazole hybrids has been reported. Hence, we have
ttempted to develop some robust statistically signifi-
ant QSAR models to predict the biological potency of
hose pyrazolo-triazole hybrids. The information gener-
ted from the QSAR could be effective to understanding
he structure – activity relationships of the series under
onsideration and subsequently design a new anticancer
ead compound.
.  Materials  and  methods
.1.  Datasets  and  biological  activity
The antiproliferative activities of several (1-benzyl-
H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-yl)
ethanone derivatives (Table 1) on different human
ancer cell lines [U87MG (brain), A549 (lung), PC3
prostate), and HT-29 (colon)] were selected from Reddy
t al. [22] to develop the chemometric tools. On the
asis of the four different cell lines, four datasets were
enerated, and the negative logarithm of the IC50 (M)
alue was considered as the dependent parameter or the
esponse variable for the QSAR models [18,20,23–25].
.2.  Generation  and  selection  of  descriptors
The 2D structures of the pyrazolo-triazole hybrids
ere drawn using ChemDraw Ultra 8.0.3 [26]. Then,
he PaDEL-Descriptors [9] were calculated for the
ompounds on the MS Windows platform. Whole
onstitutional, topological, electronic, thermodynamic,
eometric, and autocorrelation descriptors were calcu-
ated by PaDEL software. These descriptors encoded
ifferent aspects of the molecular structures and wereersity for Science 10 (2016) 896–905 897
considered as independent parameters in the chemomet-
ric models.
2.3.  Correlation  analysis
Initially, a correlation analysis was carried out with
the response variable and independent parameters of the
compounds using STATISTICA 7 software [27]. The
information less descriptors that showed no variation
between structures and/or descriptors and those that did
not cover the whole space were initially deleted from
our study [20]. One of each inter-correlated pair of vari-
ables with a correlation coefficient greater than 0.60 was
eliminated to decrease the redundancy.
2.4.  Test  set  and  training  set  selection
The splitting of datasets is very important in chemo-
metric model development because of the influence of
the chemical nature of the training set compounds on
the predictive ability of a developed QSAR model. Non-
hierarchical clustering techniques such as the K-means
clustering technique are widely used to standardize
a descriptor matrix consisting of different descriptors
[28,29]. In the K-means clustering analysis, the separa-
tion and arrangement of different objects into several
groups was performed according to their distance in
multidimensional space. In this study, we used the STA-
TISTICA 7 software [27] based K-means clustering
analysis tool.
2.5.  Stepwise  multiple  linear  regression  (S-MLR)
Stepwise multiple linear regression [18–20] meth-
ods built multistep models step by step. The following
procedures were followed to build S-MLR models.
(i) By altering the descriptor or variable combination,
a previous step was repeated with the stepping crite-
rion of F = 4 for inclusion and F = 3.99 for exclusion.
(ii) When a specified maximum number of steps had
been reached or/and when stepping is no longer pos-
sible with the given stepping criterion, the search
was terminated.
2.6.  Statistical  methods
Several validation parameters were employed to ver-
ify the statistical quality of all of the models. The
correlation coefficient (R), squared correlation coef-
ficient (R2), adjusted R2 (R2A), variance ratio (F) at
specified degree of freedom (df) and standard error of
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Table 1
Antiproliferative activities (IC50-M) of the (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-yl)methanone derivatives (1–30).
Noa R IC50 (M)
U87MG A549 PC-3 HT-29
1
O
N
N
N
NN
R
F 6.45 7.07 >50 22.4
2 Cl >50 >50 >50 >50
3 CF3 >50 >50 >50 >50
4 OCH3 8.87 7.21 4.21 5.71
5 3,4 OCH3 3.37 4.69 2.69 2.92
6 3,4,5 OCH3 7.85 5.56 6.81 4.63
7
O
N
N
N
NN
R
F
F 4.76 5.92 17.87 14.48
8 Cl 9.43 8.5 16.04 15.92
9 CF3 24.76 >50 >50 >50
10 OCH3 3.76 2.13 5.87 2.54
11 3,4 OCH3 1.14 2.3 3.34 2.48
12 3,4,5 OCH3 5.3 3.8 4.4 3.09
13
O
N
N
N
NN
R
Cl
F 8.91 4.98 >50 12.59
14 Cl 4.24 6.04 11.05 9.92
15 CF3 6.54 5.72 13.4 12.9
16 OCH3 3.3 5.3 6.3 1.78
17 3,4 OCH3 0.86 1.93 3.71 2.42
18 3,4,5 OCH3 3.95 2.42 5.62 3.5
19
O
N
N
N
NN
R
H3CO
F 15.5 13.7 9.7 14.7
20 Cl 5.89 11.21 >50 7.22
21 CF3 4.24 14.5 >50 29.11
22 OCH3 3.63 4.84 7.84 6.99
23 3,4 OCH3 0.97 2.24 3.52 1.78
24 3,4,5 OCH3 1.15 5.32 5.65 4.4
Sk.A. Amin, S. Gayen / Journal of Taibah University for Science 10 (2016) 896–905 899
Table 1 (Continued)
Noa R IC50 (M)
U87MG A549 PC-3 HT-29
25
O
N
N
N
NN
R
H3CO
H3CO
H3CO
F 18.9 >50 >50 28.6
26 Cl 26.7 >50 >50 24.1
27 CF3 8.25 >50 >50 14.72
28 OCH3 2.47 5.5 >50 4.39
29 3,4 OCH3 3.61 3.47 2.32 2.6
30 3,4,5 OCH3 3.81 6.45 5.6 3.89
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he estimate (SEE) [19,28–30] were calculated using
TATISTICA 7 software [27].
We also reported the p-value and t-value for various
arameters in each model. The effects of the intercorrela-
ion of the descriptors was further verified by the variant
nflation factor (VIF) [18,19]. A VIF value greater than
0 indicates a defective QSAR model.
IF = 1
1 −  r2
here r2 is the multiple correlation coefficient of one
escriptor’s effect regressed over the remaining molec-
lar descriptors.
.7.  Validation  of  the  2D-QSAR  Models
The leave-one-out (LOO) cross-validation method,
he predicted residual sum of squares (PRESS), and the
tandard deviation of error of prediction (SDEP) [28–30]
ere applied as internal validation tools to validate our
eveloped 2D-QSAR models. The predictive powers of
ll of the developed QSAR models were justified by these
nternal cross-validation techniques.
To predict the anti-proliferative activities of the
yrazolo-triazole hybrids, it was also important to cal-
ulate the R2pred , r2m(test), rm2(overall), rm2(overall), and
ther similar parameters. [29]. R2pred was calculated by
he equation
2 =  1 −
∑ (yi −  y¯i)2pred ∑ (yi −  ymean)2
here yi and y¯i are the actual and predicted activities of
he ‘ith’ molecule in the training set, respectively, andymean is the average activity of all molecules in the test
set.
The matrices r2m were calculated to understand both
the internal and external predictive capacities,
r2m =  r2 ×  (1 −
√
r2 −  r20)
where r2 is the squared correlation coefficient between
the observed vs predicted response values of the test set
compounds and r20 represents the corresponding values
for regression through the origin (observed vs. pre-
dicted).
The Y-randomization of the model (cR2p) was evalu-
ated to ensure that the model is not based on chance for
100 scrambling iterations [19]. Additional parameters
proposed by Golbraikh and Tropsha et al. [30] were also
determined for the developed QSAR models to ensure
robustness.
3.  Results  and  discussion
3.1.  Selection  of  training  and  test  sets
All datasets were tested on the basis of the anti-cancer
activity on human cancer cell lines [U87MG (brain can-
cer), A549 (lung cancer), PC3 (prostate cancer), and
HT-29 (colon cancer)] to develop the QSAR models
(Table 1). Each dataset (n  = 28 in U87MG cell line; n  = 24
in A549 cell line; n  = 19 in PC3 cell line; and n  = 27 in
HT-29 cell line) of the pyrazolo-triazole hybrids (Fig. 1.)
was divided on the basis of the clusters, as derived from
the K-means clustering method in STATISTICA version
7 software [27].
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m(test) m(test)Fig. 1. General structure of pyrazolo-triazole hybrids (1-benzyl-1H-
1,2,3-triazol-4-yl)(1,3-diphenyl-1H-pyrazol-4-yl) methanone.
Four clusters (three clusters in the case of the PC3
cell line) were generated, and from each cluster, 25% of
the compounds were taken at random to form the test
set. It was also ensured that the property range of the test
set compounds spans over the range of the training set
compounds. Thus, the dataset was divided into training
(nTrain = 21 in U87MG cell line; nTrain = 18 in A549 cell
line; nTrain = 14 in PC3 cell line; nTrain = 20 in HT-29 cell
line) and test (nTest = 7 in U87MG cell line; nTest = 6 in
A549 cell line; nTest = 5 in PC3 cell line; nTest = 7 in HT-
29 cell line) sets, as shown in Supplementary Table T1.
The QSAR models were generated based on the train-
ing set compounds, and the test set compounds were
taken for validation purposes. The criterion for selecting
the best model was based on the correlation coefficient.
The recommended ratio between the number of predic-
tor parameters and the number of data points was 1:5 for
all of these models [19,28,31,32].
3.2.  Stepwise  multiple  linear  regression  (S-MLR)
The correlation matrixes among descriptors used to
develop regression-based QSAR models are provided in
Supplementary Table T2.  The best models that we found
through the stepwise multiple linear regression analysis
of all of these datasets are as follows.
pIC50(U87MG) =  −28.596 (±11.939) +  0.647
(±0.128) ATSC6e  −  4.288 (±0.976) VE1  Dt
+ 9.661 (±3.333) PetitjeanNumber  +  15.183
(±5.978) Sp  Min1  Bhs.  (1)ersity for Science 10 (2016) 896–905
nTrain =  21; R  =  0.873; R2 =  0.762; R2A =  0.703;
F (4,  16) =  12.806; SEE =  0.212; Q2 =  0.554;
PRESS =  1.353; SDEP =  0.254; rm2(LOO) =  0.510;
Δrm2(LOO) =  0.156; nTest =  7; R2pred =  0.866;
r2m(test) =  0.723; Avg  r2m(test) =  0.765;
Δr2m(test) =  0.083; rm2(overall) =  0.566;
Δrm2(overall) =  0.051; cR2p  =  0.638.
pIC50(A549) =  3.033 (±0.580) −  6.977 (±1.090)
MATS8c  +  205.629 (±51.458) JGI10  +  0.050
(±0.017) VR3 Dzp  +  0.187 (±0.074)VE3 Dzv.  (2)
nTrain =  18; R  =  0.879; R2 =  0.772; R2A =  0.703;
F (4,  13) =  11.020; SEE =  0.118; Q2 = 0.637;
PRESS =  0.290; SDEP =  0.127; rm2(LOO) =  0.590;
Δrm2(LOO) =  0.120; nTest =  6; R2pred =  0.858;
r2m(test) =  0.637; Avg  r2m(test) =  0.542;
Δr2m(test) =  0.188; rm2(overall) =  0.697;
Δrm2(overall) =  0.219; cR2p  =  0.687.
pIC50(PC – 3) =  53.755 (±8.220) −  3.823 (±0.428)
AATS6e  −  295.415 (±  96.956) ASP– 7 −  8.421
(±2.892) SpMin6  Bhi.  (3)
nTrain =  14; R  =  0.953; R2 =  0.908; R2A =  0.880;
F (3,  10) =  32.881; SEE =  0.078; Q2 =  0.850;
PRESS =  0.0993; SDEP =  0.084; rm2(LOO) =  0.822;
Δrm2(LOO) =  0.059; nTest =  5; R2pred =  0.796;
r2 =  0.657; Avg  r2 =  0.553;
Δr2m(test) =  0.207; rm2(overall) =  0.787;
Δrm2(overall) =  0.148; cR2p  =  0.833.
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Table 2
VIF, t-value and p-value for Models (1)–(4).
Parameter t-value p-value VIF
Model (1)
Intercept −2.395 0.029 –
ATSC6e 5.055 0.000 1.057
VE1 Dt −4.391 0.000 1.390
PetitjeanNumber 2.898 0.010 1.115
SpMin1 Bhs 2.539 0.021 1.326
Model (2)
Intercept 5.227 0.000 –
MATS8c −6.401 0.000 1.456
JGI10 3.996 0.001 1.422
VR3 Dzp 2.883 0.012 1.543
VE3 Dzv 2.507 0.026 1.630
Model (3)
Intercept 6.539 0.000 –
AATS6e −8.937 0.000 1.999
ASP-7 −3.046 0.012 2.189
SpMin6 Bhi −2.911 0.015 1.655
Model (4)
Intercept −2.166 0.045 –
AATSC8c −11.275 0.000 1.992Sk.A. Amin, S. Gayen / Journal of Taib
nd
IC50 (HT – 29) =  −17.371 (±8.018) −  819.204
(±72.655) AATSC8c  +  6.953 (±0.798) VE1  Dzv
+ 9.997 (±4.207) SpMin3 Bhs.  (4)
Train =  20; R  =  0.962; R2 =  0.926; R2A =  0.912;
F (3,  16) =  66.924; SEE =  0.118; Q2 =  0.891;
PRESS =  0.326,  SDEP =  0.128; rm2(LOO) =  0.879;
Δrm2(LOO) =  0.060; nTest =  7; R2pred =  0.707;
r2m(test) =  0.488; Avg  r2m(test) =  0.575;
Δr2m(test) =  0.174; rm2(overall) =  0.769;
Δrm2(overall) =  0.062; cR2p  =  0.827.
Model (1) and Model (2) both explain 70.3% and pre-
ict 55.4% and 63.7% of the variances of the U87MG and
549 cell line anti-proliferative activities, respectively,
hereas Model (3) explains 88% and predicts 85% of
he variance of the PC-3 cell line inhibition. The highest
xplanation and predictive ability are shown by Model
4), which can explains 91% and predict 89% of the vari-
nces of the HT-29 cell line antiproliferative activity. The
IF, t-value and p-value for Models (1)–(4) are shown
n Table 2.
The differences between the R2 and Q2 values of all
odels are less than 0.30. All models showed rm2(LOO)
alues greater than 0.50 and have good predictive abil-
ty, as indicated by R2pred values higher than 0.50. These
our models demonstrated Avg  r2m(test) and rm2(overall)
alues greater than 0.50. The validation metric values
re within the acceptable limits, confirming the accept-
ble overall fitting of these models. The values found for
he cR2p  (model randomization) of all models are much
reater than the threshold value of 0.50, ensuring that the
odels are not the outcome of mere chance alone. The
tatistical results are listed in Table 3. Additionally, the
our models satisfied the acceptability criteria suggested
y Golbraikh and Tropsha (Table 4). The observed, cal-
ulated, residual, predicted residual, and LOO-predicted
ctivities of the training set compounds of Model (1)–(4)
re shown in Supplementary Table T3. The observed
nd predicted values of the test set compounds of Mod-
ls (1)–(4) are provided in Supplementary Table T4.
he observed (Obs) vs. LOO-predicted (Pred) activities
f the training set compounds for Models (1)–(4) are
lotted graphically in Fig. 2. It is very interesting thatVE1 Dzv 8.717 0.000 1.571
SpMin3 Bhs 2.376 0.030 1.499
compounds 11, 17, 23 have a potent broad spectrum of
activities against all of the tested cancer cell lines. To
check the significance of the developed QSAR models,
the predicted biological activities of these compounds
were compared with the observed activities, suggesting
good agreement (Supplementary Table T5).
3.3.  Descriptor  Contributions  in  the  QSAR  models
3.3.1.  Model  1
ATSC6e  is defined as the centred Broto-Moreau
autocorrelation – lag 6/weighted by the Sanderson elec-
tronegativities [33]. The electronegative substituent, e.g.,
F or Cl, decreases whereas electron-donating group, e.g.,
methoxy, increases the value of the coefficient ATSC6e.
It shows a positive impact on the biological activity.
Compound 23 has the highest ATSC6e  value and has
methoxy substitutions on both the A and B ring. Thus,
this compound is the most potent against the U87MG
cell line.
VE1 Dt  represents the cocoefficient sum of the last
eigenvector from the detour matrix [34]. The negative
coefficient of VE1  Dt  implies that with the increase
of these values, the glioblastoma cell inhibitory activ-
ity of the pyrazolo-triazole hybrids may be decreased.
The presence of this descriptor in the QSAR model
suggests that three methoxy substitutions in the A-
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Table 3
Important statistical parameters of Models (1)–(4).
Model nTrain R R2A SEE Q2 PRESS rm2(LOO) nTest R2pred r2m(test) rm2(overall) cR2p
1 21 0.873 0.703 0.212 0.554 1.353 0.510 7 0.866 0.723 0.566 0.638
2 18 0.879 0.703 0.118 0.637 0.290 0.590 6 0.858 0.637 0.697 0.687
3 14 0.953 0.880 0.078 0.850 0.0993 0.822 5 0.796 0.657 0.787 0.833
6 4 20 0.962 0.912 0.118 0.891 0.32
ring are unfavourable (compounds 25–30), whereas
di- or tri-methoxy substitutions are preferable in the
B ring.
SpMin1  Bhs  and  PetitjeanNumber  have positive con-
tributions towards the anti-proliferative activity of the
analogues on cancerous U87MG cell lines. SpMin1  Bhs
demonstrates the smallest absolute eigenvalue of the
Burden modified matrix – n 1/weighted by the rel-
ative I-state. Fluorine/fluorine-containing substituents,
e.g., CF3, decrease the values of the coefficient and
so are detrimental to the activity. The PetitjeanNum-
ber is defined as the shape of the cation. The value
of the shape parameter PetitjeanNumber  increases
when the substituents are changed from F or Cl to
CF3 or OCH3 on the B ring, which increases the
activity.
3.3.2. Model  2
MATS8c  negatively contributed towards the antipro-
liferative activity on A549 cell lines. It represents the
Moran autocorrelation lag 8/weighted by charges [34].
Compound 17 has the lowest MATS8c  value, and it shows
the highest biological potency on the lung cancer cell
line.
JGI10 is the mean topological charge index
of order 10 [34], and it demonstrated a positive
impact on the lung cancer cell line inhibition. The
mean topological charge index can be increased by
adding high-electronegativity compounds to the A
Table 4
Golbraikh and Tropsha acceptable model criteria of Models (1)–(4).
Sl. No. Parameter Threshold value Model (
(i) Q2 Q2 > 0.5 0.55422
(ii) r2 r2 > 0.6 0.90963
(iii) |r20 − r20′ | |r20 − r20′ | < 0.3 0.04583
(iv) k 0.85 < k < 1.15 1.00128
(v) k′ 0.85 < k′ < 1.15 0.99798
(i) Q2 is the cross-validated correlation coefficient, (ii) Parameter r2 is the squa
values of the test set compounds, (iii) r20 and r20′ represent the corresponding
predicted vs. observed, respectively), (iv) The slopes of the regression lines th0.879 7 0.707 0.488 0.769 0.827
ring of (1-benzyl-1H-1,2,3-triazol-4-yl)(1,3-diphenyl-
1H-pyrazol-4-yl)methanone derivatives (compound 7,
10, 13, 15, 16, 21).
VR3  Dzp  is defined as the logarithmic Randic-
like eigenvector-based index from the Barysz
matrix/weighted by polarizabilities, whereas VE3  Dzv
represents the logarithmic coefficient sum of the last
eigenvector from the Barysz matrix/weighted by the
van der Waals volumes [34]. These two descriptors
positively contributed towards the A549 cell line
inhibition, which means that compounds having good
VR3 Dzp  and VE3  Dzv  values will show promising
antiproliferative activity.
3.3.3.  Model  3
AATS6e  is defined as the average Broto-Moreau
autocorrelation – lag 6/weighted by the Sanderson elec-
tronegativities [34]. The negative coefficient of AATS6e
implies that with a decrease in the value of AATS6e, the
prostate cancer cell inhibitory activity of the pyrazolo-
triazole hybrids will increase. The highest and lowest
AATS6e values are shown by compound 7 (contain-
ing an electron-withdrawing group) and compound 23
(bearing an electron-donating group), respectively. Thus,
electronegativity on the B-ring of the pyrazolo-triazole
hybrid is detrimental to the PC-3 cell line inhibition.
ASP-7 (ChiPath Descriptor Average simple path,
order 7) and SpMin6  Bhi  (smallest absolute eigenvalue
of Burden modified matrix – n 6/weighted by relative first
1) Model (2) Model (3) Model (4)
 0.63712 0.85033 0.8912
 0.94474 0.84756 0.82154
 0.21287 0.2568 0.08512
 0.99564 1.00085 1.01793
 1.00391 0.99842 0.98127
red correlation coefficient between the observed vs predicted response
 values for regression through the origin (observed vs. predicted and
rough the origin are assigned by k and k′.
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Fig. 2. Graphical representation of Observed (Obs) versus LOO-
p
(
i
i
t
h
o
spectrum anticancer compounds against all of the testedredicted (Pred) activities of training set compounds for (a) Model
1), (b) Model (2), (c) Model (3), (d) Model (4).
onization potential) negatively contributed towards the
nhibition of prostate cancer cell lines [33]. The poten-
ial anticancer activity shown by compounds 4 and 5
ad a low ionization potential compared with that of
thers.ersity for Science 10 (2016) 896–905 903
3.3.4.  Model  4
AATSC8c  shows a negative impact on the HT-29 cell
line antiproliferative activity. It denotes the average cen-
tred Broto-Moreau autocorrelation – lag 8/weighted by
charges [34]. Substitution on the B ring of pyrazolo-
triazole hybrids with trifluoromethyl may lead to a less
active molecule against colon cancer cell lines (com-
pounds 15, 27).
VE1  Dzv  is the coefficient sum of the last eigenvec-
tor from the Barysz matrix/weighted by van der Waals
volumes [34]. It positively contributed towards the inhi-
bition of colon cancer cell lines.
SpMin3  Bhs  is defined as the smallest absolute eigen-
value of the Burden modified matrix – n 3/weighted by
the relative I-state [34]. The positive contribution shown
by SpMin3  Bhs  indicates that the biological potency can
be increased by increasing the SpMin3  Bhs  value. Upon
the addition of an electronegative atom or an electron-
withdrawing group to ring B of these hybrid derivatives,
there was a dramatic loss in the antiproliferative activ-
ity of the HT-29 cell lines (compounds 1, 7, 13, 19,
and 25).
4.  Conclusions
In conclusion, very important indications emerge
from our QSAR study of pyrazolo-triazole hybrids
(Fig. 3). The QSAR models suggest the importance of
descriptors, such as ATSC6e, VE1  Dt, PetitjeanNumber,
SpMin1 Bhs,  MATS8c,  VR3  Dzp, ASP-7  SpMin6  Bhi,
AATSC8c, VE1  Dzv  and SpMin3  Bhs. The QSAR study
revealed that the tri-methoxy substitution on the A-
ring was unfavourable for the antiproliferative activity
(negative contribution of VE1  Dt), whereas the posi-
tive contribution of JGI10  suggested that the addition
of electronegative atoms on the A-ring of pyrazolo-
triazole hybrids leads to potent anti-cancer compounds.
In the B-ring, trifluoromethyl and strong electroneg-
ative group substitutions were not suitable (negative
contribution of AATSC8c  and positive contribution of
SpMin3 Bhs, respectively), but 3,4-OCH3 substitution
into the pyrazolo-triazole hybrid compound was prefer-
able (positive contribution of ATSC6e) for anticancer
activity. Thus, an electronegative substituent at the p-
position in the A ring and a 3,4-OCH3 substituent in the
B ring make compounds 11, 17, and 23 potent broadcell lines. This study also presents a rationale for choos-
ing a hybrid moiety for anti-cancer drug design and
development.
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